Julian Harrison
Stock Analyst at BTIG
(1.02)
# 3,627
Out of 4,847 analysts
37
Total ratings
32.26%
Success rate
-14.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.35 | +819.54% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $9.87 | +325.53% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.66 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $21.86 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.77 | +408.47% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.44 | +455.56% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $0.93 | +762.07% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $14.00 | +335.71% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.23 | +255.03% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $16.87 | +48.19% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $50.15 | +1.69% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $6.35 | +577.17% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $15.40 | +159.74% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $11.15 | +88.34% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $36.31 | +18.42% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.25 | +23.08% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.82 | +18,192.68% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $41.16 | -12.54% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $325.48 | - | 2 | Feb 11, 2022 | |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.35
Upside: +819.54%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $9.87
Upside: +325.53%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.66
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $21.86
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.77
Upside: +408.47%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.44
Upside: +455.56%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.93
Upside: +762.07%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $14.00
Upside: +335.71%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.23
Upside: +255.03%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $16.87
Upside: +48.19%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $50.15
Upside: +1.69%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $6.35
Upside: +577.17%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $15.40
Upside: +159.74%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $11.15
Upside: +88.34%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $36.31
Upside: +18.42%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.25
Upside: +23.08%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.82
Upside: +18,192.68%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $41.16
Upside: -12.54%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $325.48
Upside: -